Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 139 publications
Correction: CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors.
Journal: The Journal of experimental medicine
Published: July 30, 2026
Response of undifferentiated and dedifferentiated endometrial cancer to pembrolizumab: a case report.
Journal: Anti-cancer drugs
Published: December 24, 2025
Temporary intraperitoneal breast implant spacer to facilitate safe stereotactic body radiotherapy for recurrent high-grade serous ovarian carcinoma.
Journal: Gynecologic oncology reports
Published: December 10, 2025
Interval versus primary cytoreductive surgery in BRCA-mutated advanced-stage ovarian/peritoneal/tubal carcinoma.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: October 01, 2025
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 13, 2025
Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 13, 2025
The use of PARP inhibitors as maintenance therapy in ovarian carcinosarcoma: A case series.
Journal: Gynecologic oncology reports
Published: June 04, 2025
Maintenance bevacizumab following chemotherapy is associated with improved survival in patients with advanced and recurrent cervical cancer in a single-institution retrospective study.
Journal: Gynecologic oncology reports
Published: January 01, 2025
Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 20, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 03, 2024
Prolonged treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing.
Journal: Gynecologic oncology reports
Published: June 07, 2024
Extended-duration antibiotics are not associated with a reduction in surgical site infection in patients with ovarian cancer undergoing cytoreductive surgery with large bowel resection.
Journal: Gynecologic oncology
Published: January 30, 2024
Last Updated: 09/26/2026